Study on the Screening of Acute Exacerbation Biomarkers and Mechanism of Interstitial Lung Disease Based on Metabolomics Technology

Study on novel biomarkers for acute exacerbation of interstitial lung disease

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400084101

Enrollment

Unknown

Registered

2024-05-10

Start date

2024-05-16

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Interstitial lung disease

Interventions

Healthy control group:None

ILD stable period group:None

The AE-ILD group:None

AE-ILD group (Extended sample size validation cohort):None

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: This was consistent with the diagnostic criteria for AE-ILD in 2016 (1) Significant deterioration of respiratory symptoms within one month; (2) There are new abnormalities in HRCT, such as diffuse, bilateral glass grinding changes;

Exclusion criteria

Exclusion criteria: (1) There are other obvious clinical causes, such as fluid overload, left heart failure, or pulmonary embolism. (2) Obvious bacterial pneumonia patients.

Design outcomes

Primary

Measure	Time frame
Novel biomarkers for serum;Novel biomarkers of alveolar lavage fluid;Mortality at 28 days and 90 days;	—

Secondary

Measure	Time frame
ICU stay;Hospitalization expenses;Mechanical ventilation time;	—

Countries

China

Contacts

Public ContactBi Chen

Affiliated Hospital of Xuzhou Medical University

chenbi207@126.com+86 150 0520 7551

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026